Recombinant Human CXCL5 protein (mFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

mFc Tag

Activity

not tested

Cat no : Eg4041

---

Validation Data Gallery

• 

  Purity of Recombinant Human CXCL5 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CXCL5 protein Ala37-Asn114 (Accession# P42830) with a mouse IgG Fc tag at the C-terminus.
• GeneID: 6374
• Accession: P42830
• PredictedSize: 35.0 kDa
• SDS-PAGE: 35-40 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CXCL5 is a member of the ELR+ CXC chemokine family, whose members contain a highly conserved three amino acid motif (ELR+) that promotes angiogenesis and is highly associated with aberrant angiogenesis. CXCL5 is an important chemokine secreted by immune cells, such as monocytes and T lymphocytes. Recent studies indicated that CXCL5 is aberrantly expressed in >14 different types of cancer, including hepatocellular carcinoma, prostate cancer, pancreatic cancer, and gastric cancer. Antibody neutralization of CXCL5 in experimental models of human non-small-cell lung cancer decreased tumor angiogenesis and metastasis.

References:

1. Robert M Strieter. et al. (2004) Semin Cancer Biol. 14(3):195-200.
2. R M Strieter. et al. (1995) J Biol Chem. 270(45):27348-57.
3. Morgan O'Hayre. et al. (2008 )Biochem J. 2008 Feb 1;409(3):635-49.
4. Gildas Lepennetier. et al. (2019)J Neuroinflammation. 16(1):219.
5. Wen Zhang. Et al. (2020)Cancer Commun (Lond). 40(2-3):69-80.